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1. Introduction
Amyloidosis is a term used for some clinical disorders that result from deposition of in‐
soluble amyloid fibrils in extra- and intracellular spaces leading to many tissue dysfunc‐
tions and disrupt tissue architectures in human body. These set of disorders with similar
pathophysiology, and involvement of metabolic pathways result in protein deposition in
different tissue.[1-3]
Amyloid deposits in various groups of amyloidosis have these common findings:
1. Homogeneous granular, filamentous eosinophilia in hematoxylin and eosin staining.
2. Metachromasia in crystal violet staining.
3. Ultraviolet fluorescence in Thioflavin-T staining
4. Orange-red staining with Congo red, which exhibits two additional properties – Bire‐
fringence (ability to rotate polarized light by 90°) and Dichroism (red to green color
change under polarized light).
These amyloid proteins can be classified into:
a. Immunoglobulin light chains (AL) in primary systemic amyloidosis.
b. Amyloid A protein (AA) in secondary amyloidosis.
c. Transthyretine in familial amyloidosis.
d. A protein known as Amyloid P component (AP ). These conditions may be primary or
secondary, localized or systemic, and familial or nonfamilial. Primary systemic amyloi‐
dosis includes so many clinical disorders like heart failure, gastrointestinal tract in‐
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volvement, neuropathies, and other disorders. Secondary systemic amyloidosis results
from chronic inflammatory diseases such as tuberculosis or syphilis. [4-8]
Various ocular structures may be involved in any subgroup of systemic amyloidosis, as well
as in localized amyloidosis limited to the eye. We will discuss in detail in this chapter about
ocular manifestations of amyloidosis. Table-1 summarizes ocular involvements of different
subgroups of amyloidosis.
Structure Involvement Amyloidosis Classification Comment
Eyelids ,Orbit & Adnexa Waxy eyelid papules with purpura, Primary Systemic
Proptosis, diplopia, Ptosis,
accommodative paresis
Primary localized, primary systemic
Keratoconjunctivitis sicca, upper lid
mass
Primary localized, primary systemic,
secondary systemic
Conjunctiva Tumefactive or diffuse yellow infiltrative
masses
Primary localized, secondary
localized, primary systemic
Cornea Polymorphic Amyloid Degeneration Primary localized Secondary to climatic Effects
Primary Gelatinous Drop-Like Dystrophy Primary localized Autosomal-Dominant
Inheritance
Lattice Stromal Dystrophy (Type I, III) Primary localized Autosomal-Dominant
Inheritance
Lattice Stromal Dystrophy (Type II =
Meretoja Syndrome )
Primary systemic Autosomal-Dominant
Inheritance with Systemic
Symptoms
Anterior Chamber Particulate glaucoma Heredofamilial (neuropathic)
Scalloped pupils, amyloid particles
pupillary margin
Heredofamilial (neuropathic),
primary systemic
Retina and Vitrous Fundus abnormalities, decreased vision Heredofamilial, I and II
(neuropathic)
Table 1. Amyloidosis presentations in different ocular tissue
1.1. Periorbital and orbital amyloidosis
Ophthalmic presentations of Amyloidosis are not a common entity. Amyloidosis can affect
any ocular and periocular structures with multifarious clinical presentations so reaching to
correct diagnosis is often an arduous task. Periocular and orbital amyloidosis is generally a
slowly progressive disease, but it potentially can lead to devastating ocular complications.
The most common signs and symptoms include: visible or palpable periocular mass or tis‐
sue infiltration and ptosis. Other less common signs are; pain or periocular discomfort, re‐
current periocular subcutaneous haemorrhages, keratoconjunctivitis sicca, ocular motility
disturbances, pupillary abnormalities, proptosis and globe displacement. Proptosis may re‐
sult from a localized orbital mass or from diffuse amyloid infiltration. Mild pain or painless
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status in clinical presentations of ocular amyloidosis can differentiate this disease from idio‐
pathic inflammatory pseudotumor.[9-11]
In this section different involvements of periorbital tissues by amyloidosis will be discussed
in detail.
2. Eyelid involvement
Dermal and ocular amyloidosis can affect eyelid skin either as a part of primary systemic
amyloidosis or secondary to dermal conditions like basal cell carcinoma, Bowen’s disease
and seborrhoeic keratosis.
Nodular or diffuse deposits of amyloid in eyelids are either unilateral or bilateral. Eyelids
can be either isolated site of involvement or get involved beside the other sites (e.g. scalp,
head and neck or axillae).
Eyelid skin is the preferred site of amyloid deposits both in primary and secondary (reac‐
tive) amyloidosis; so unlike other periocular amyloidoses, eyelid skin involvement indicates
systemic workup for presence of systemic disease and even some ophthalmologists believe
that cutaneous involvement of the eyelid is a sign of primary systemic amyloidosis unless
otherwise proved; on the other hand periocular involvements that spares eyelid skin is
probably localized.
Amyloid protein deposits in the eyelid skin vessel walls and secondarily increase their fra‐
gility, making them very susceptible to hemorrhage after minor trauma (or even spontane‐
ously), so waxy eyelid papules with hemorrhagic appearance can be diagnostic clue of
systemic amyloidosis.
Dermatologic conditions like basal cell carcinoma, Bowen’s disease, and seborrheic keratosis
can lead to secondary localized forms of amyloid deposits in the eyelids although this condi‐
tion is a histopathologically incidental finding.
 
(a) (b) 
Figure 1. Waxy eyelid papules (A ) with hemorrhagic appearance (B ) in systemic amyloidosis Sophie R Silverstein MB
BChir MA; Primary, systemic amyloidosis and the dermatologist: Where classic skin lesions may provide the clue for
early diagnosis; Dermatology Online Journal 11 (1): 5
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Primary localized cutaneous amyloidosis of eyelid is not a common condition and can be
overlooked easily. In this condition we can see Amyloid light chains (AL) deposits in the tis‐
sue. As this condition is usually associated with B-cell or Plasma cell proliferation so plasma
cell dyscrasia must be excluded.[9,11,12-16]
3. Orbital involvement
Orbital involvement is more common in primary compared to secondary amyloidosis and is
rare in hereditary/familial or senile amyloidosis. Localized amyloidosis is a rare condition
usually affecting head and neck region and only 4% of them involve orbital region. Al‐
though some sight threatening complications like secondary glaucoma and optic neuropa‐
thy have been reported, orbital localized amyloidosis is usually considered a benign
condition with a slowly progressive nature.
Two types of localized orbital amyloidosis have been described. One type presents with pro‐
gressive proptosis and limitation of ocular movements and is associated with bilateral nodu‐
lar infiltration of extraorbital muscles and nearby adnexal tissues. Second form is rare cases
of Amyloidoma that occurs usually in anterior orbital region next to lacrimal glands. These
Amyloidomas have yellow waxy appearances with fragile consistency that shows calcifica‐
tion in orbital CT-scan. [10, 17-22]
Ptosis and Ophthalmoplegia are two common clinical presentations of periocular involve‐
ment that can occur coincidentally or respectively (ophthalmoplegia may follow the ptosis
by weeks or months). These two manifestations are due to infiltration and secondary ne‐
crosis of extraocular muscles, including levator and Muller’s Muscles.
Although Extra-Ocular muscle involvements can present with proptosis, ocular motility re‐
strictions or diplopia, in some cases no prominent signs suggestive of this involvement can
be found and Orbital imaging is necessary to make the accurate diagnosis.[9-11,23]
Lacrimal gland involvement is not common in amyloidosis and most commonly presents
with hard and mobile Superior-temporal orbital mass, rarely fixated to periocular bones.
Other manifestations include proptosis, ocular motility disorders, keratoconjunctivitis Sicca
and mild pain.
Amyloid  deposits  in  systemic  Amyloidosis  involve  lacrimal  glands  bilaterally,  whereas
primary localized amyloidosis usually affects them unilaterally.  Lacrimal Gland involve‐
ment can mimic disorders like vascular malformations, dacryoadenitis,  or lacrimal gland
neoplasms.
Computed tomography and MRI although not diagnostic but are important in localizing the
involved orbital structures. Lacrimal gland involvement on orbital CT scan usually presents
as a homogenous mass, with a slightly higher density than brain with involvement of near‐
by extra-ocular muscles, although sometimes lobulated gland with areas of calcification and
orbital wall erosion can be seen.
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Figure 2. Patient-1. (a) Right-sided ptosis. (b) Orbital mass prolapsing through the right upper fornix. (c) and (d) Intra‐
operative photographs at the time of biopsy. (e) First CT orbits showing the right-sided orbital mass. (f) Repeat CT 9
years later showing the mass to be unchanged. Patient-2. (g). Translucent, yellow, and nodular orbital mass prolapsing
through the left upper fornix. (h) MRI of orbits showing the mass in the left orbit. S Dinakaran, A D Singh and I G Ren‐
nie: Orbital amyloidosis presenting as ptosis; Eye (2005) 19, 110–112. doi:10.1038/sj.eye.6701411
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Although both CT and MRI can be useful in detecting the involvement of periocular tissue
in amyloidosis, CT scan is generally more informative than MRI because of the higher sensi‐
tivity in detecting specific bone changes and calcifications.
The mass effect can cause globe displacement. Extraocular muscle enlargement, soft tissue
infiltration/mass, and calcifications are also characteristic findings on imaging and are seen
almost always in orbital involvement.
Other signs of extra-ocular muscle involvement include highly irregular nodular enlarge‐
ment of muscles with extension to nearby fat tissue with a reticular pattern, fusiform en‐
largement of muscles with islands of calcification. Extraocular muscle tendons usually are
spared. and muscle involvement may be either unilateral or bilateral. [ 9,11,22-26]
4. Optic nerve involvement
Although orbital amyloidosis rarely involves optic nerve primarily, orbital or muscular
amyloid masses especially those located at the orbital apex can involve optic nerve seconda‐
rily and can lead to vision loss. Moreover compressive optic neuropathy secondary to dural
infiltration is another cause of optic nerve involvement. As a rule, the neuropathic amyloi‐
dosis spares the optic nerve.[9-11]
5. Conjunctival involvement
A primary localized form of Amyloidosis is Amyloid plaque deposition in substantia prop‐
eria of the conjunctiva that usually occurs in healthy young and middle-aged persons with
no sex predilection.
The conjunctiva can either be the only site of involvement or involve as well as other struc‐
tures like the orbicularis occuli or levator muscles. Nodular or diffuse amyloid deposits in
these structures can clinically present with Salmon patch nodules and blephariptosis. Con‐
junctival amyloidosis usually involves the fornixes (superior fornix more than inferior) and
tarsal conjunctiva. Amyloid deposits may be unilateral or bilateral and have firm or rubbery
and waxy appearance.
Conjunctival deposits are usually painless, but may cause epiphora or significant local swel‐
ling and irritation. Recurrent subconjunctival haemorrhages is another presenting symptom
of conjunctival amyloidosis that can be missed easily and is usually due to increased fragili‐
ty of orbital vasculature secondary to amyloid deposits.
Although initial systemic evaluation for primary systemic amyloidosis in patients with con‐
junctival deposits is usually negative, progression of a local primary-amyloidosis to a sys‐
temic disease has been reported and should be kept in mind when following a presumed
localized amyloid patient. Although disorders like trachoma, recurrent bacterial conjunctivi‐
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tis, or immune conjunctival involvements like GVHD can lead to secondary conjunctival
Amyloidosis, this is not a common phenomenon.
 
(a) (b) 
Figure 3. A. Tumefactive conjunctival amyloidosis.B. Nodular amyloid infiltration of the conjunctiva with spontaneous
hemorrhage. Albert & Jakobiec's Principles & Practice of Ophthalmology- 3rd Ed,2008,Vol 3,chapter 331,Page
4524,4525
In review of literatures some reports can be seen about conjunctival amyloid deposits after
recent strabismus surgery and conjunctival involvement secondary to reactive systemic
amyloidosis in rheumatoid arthritis.[9-11, 27-33]
6. Management of periocular and ocular amyloidosis
For diagnosis of periorbital and orbital amyloidosis usually tissue biopsy is required and
Congo red staining shows characteristic  red-green dichroism in  unidirectional  polarized
light.
The first  step in  management  of  periocular  amyloidosis  is  determining the  type of  dis‐
ease and coincidental systemic involvement. Some treatment modalities like Surgical de‐
bulking,  radiotherapy and observation have been descried for  localized amyloidosis  but
surgical debulking remained mainstay of treatments in patients with symptomatic diseas‐
es including ocular motility disturbances,  compressive optic neuropathy, and unaccepta‐
ble cosmetic appearance.
In patients with medical contraindications for surgery or with extensive infiltrative disease,
radiotherapy either with or without surgical debulking may be useful.
Observation is a choice of treatment in asymptomatic or mildly symptomatic patients with
localized amyloidosis.
Because complete surgical excision of periocular masses is not possible in most patients, and
some case reports showed significant progression after surgical debulking, often symptom
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revealing treatments for restoration of visual functions and prevention of ocular complica‐
tions is the goal of treatment.
For Extensive conjunctival infiltration close follow-up is the best option because surgical re‐
moval and other modalities are not effective for these lesions.[9-11]
7. Anterior chamber involvement
Anterior chamber involvement is usually accompanied by vitroretinal involvement in he‐
reditary systemic amyloidosis. Clinical manifestations in this form of involvement include
white flocculent debris in aqueous, anterior lens capsule and on the iris surface and scal‐
loped pupil borders that indicate amyloid deposition in iris stroma or disruption of para‐
sympathetic innervation of the iris sphincter.
Hallmark of ocular amyloidosis presenting in anterior chamber is amyloid glaucoma that
is very similar to pseudoexfoliation syndrome and only microscopic studies can differen‐
tiate these entities. A close relationship between the onset of glaucoma and pupillary ab‐
normalities  has  been  described  in  this  condition.  This  is  a  unilateral  asymmetric
condition with multiple mechanisms involved in its pathophysiology. Increased episcleral
venous  pressure  secondary  to  perivascular  amyloid  deposition  and increased  resistance
to  aqueous  outflow  are  two  probable  mechanisms  of  increased  intra-ocular  pressure
(IOP) in this situation. Familial amyloid polyneuropathy (FAP) is often complicated with
glaucoma and vitreous opacity.
As previously mentioned amyloid deposition on the pupil border is a strong predictor of
glaucoma. It is proposed that fringed pupil may be secondary to high amount of amyloid
deposit on the pupil border and these deposits may involve trabecular meshwork, reduce
aqueous outflow and secondarily increase intra-ocular pressure (IOP).
Medical management with aqueous suppressants is treatment of choice to decrease IOP but
vitrectomy may have some benefits in aphakic eyes. [34-40]
8. Iris involvement
As in amyloid glaucoma, iris stromal deposits originated from blood vessels in amyloidosis
is associated with vitreoretinal diseases and usually occur in familial amyloid polyneurop‐
athy (FAP ).
Scalloped border pupils have been found to be the classic sign of iris involvement in amyloi‐
dosis, although not a pathognomonic sign.
Secondary localized Amyloidosis has been reported after conditions like recurrent or chron‐
ic uveitis and rare disease like ocular leprosy.
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Figure 4. Scalloped pupil seen in heredofamilial neuropathic amyloidoses. From Lessell S, Wolf PA, Benson MD, Cohen
AS: Scalloped pupils in familial amyloidosis. Reprinted from the New England Journal of Medicine, 1975; 293:914–915.
Histopathological review of eyes from patients with rheumatoid arthritis has showed amy‐
loid deposition in iris and posterior uvea. More than the iris, the choroid may also be infil‐
trated with amyloid in patients with primary systemic amyloidosis.
There are some reports of pupillary abnormality such as pupillary deformity, decrease in
pupillary reaction to light, and amyloid deposition in the pupillary border. [34-35,41,42]
9. Vitreoretinal involvement
Vitreous Amyloidosis as a rare condition usually presents in Familial Amyloid Polyneurop‐
athy (FAP) but isolated vitreous deposits in the absence of a family history (primary nonfa‐
milial amyloidosis of the vitreous) are extremely rare. FAP usually results from mutations in
transthyretin (TTR) gene and is the most common form of hereditary amyloidosis. Although
TTR (also known as prealbumin) is usually produced in the liver, retinal pigment epitheli‐
um and choroid plexus of brain can synthesize this protein too. TTR transfers thyroxine and
retinol binding proteins in plasma.
Vitreous opacities, manifested as bilateral (but highly asymmetric) cobweb-like or sheet-like
veils or string of pearls white opacities are the most common presentations of this condition,
and density of this opacities determines severity of visual symptoms. These symptoms in‐
clude glare, floater, blurred vision and acute decrease in vision secondary to dislocation of
these opacities to the visual axis. These vitreous opacities usually spread from cortical vitre‐
ous to the center and are often the only sign of ocular involvement but can be in association
with other signs like Iris deposits, choroidal infiltration and amyloid glaucoma. Unfortu‐
nately this condition can be misdiagnosed easily with uveitis, vitritis, intra-ocular lympho‐
ma, and vasculitis. In FAP, vitreous opacity incidence is variable between 5.4% and 35%.
Vitreous involvement in FAP may be accompanied by other organs involvement so systemic
workup is necessary.
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Retinal vessels usually appear normal in vitreous involvement, although sometimes these
opacities may involve perivascular regions and appear as focal plaques, tortuosity, beading
or vascular sheathing. Retinal vasoocclussive accidents that appear as cotton-wool spots and
neovascularizations have been reported too.
Figure 5. Congo red preparation of amyloid infiltration of outer retinal vessel wall. From Schwartz MF, Green WR, Mi‐
chels RG, et al: An unusual case of ocular involvement in primary systemic nonfamilial amyloidosis. Ophthalmology
1982; 89:394–401.
Figure 6. Typical lens footplates seen in advanced vitreous amyloidosis (deposits aligning themselves on posterior lens
capsule). From Doft BH, Machemer R, Skinner M, et al: Pars plana vitrectomy for vitreous amyloidosis. Ophthalmology
1987; 94:607–611.
Retinal hemorrhages with dot and linear shapes may be seen. In angiography, retinal vascu‐
lar involvement present with blockage from vasocclusive abnormalities and focal or diffuse
leakage that is more prominent in posterior pole than retinal periphery. Another clinical
presentation of vitreous amyloidosis is central vitreous opacities that make footplate-like
opacities on the posterior lens capsule.
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In OCT (optical coherence tomography) veil like vitreous opacities shows needle-shaped de‐
posits on the retinal surface that extend to the vitreous cavity and immunohistochemistry
studies demonstrate amyloid-light chain deposits.
Figure 7. Magnified view of vitreous opacification. From Schwartz MF, Green WR, Michels RG, et al: An unusual case of
ocular involvement in primary systemic nonfamilial amyloidosis. Ophthalmology 1982;89:394–401.
Treatment modalities for vitreous amyloidosis is limited to vitrectomy and leads to signifi‐
cant visual improvement, but unfortunately opacities can reoccur in one-fourth of patients
over months. Incomplete vitrectomy proposed as the reason of this amyloid reaccumulation.
Tight adhesion of these opacities to the perivascular regions potentially can lead to forma‐
tion of retinal breaks during surgery.
Glaucoma as an independent condition in vitreous amyloidosis or concurrently developed
complication, can be managed with filtering surgery at the time of vitrectomy or at any time
postoperatively.[43-55]
10. Amyloidosis of the cornea
The Cornea as an important transparent structure of human visual system can be affect‐
ed in Systemic and localized amyloidosis, either as a primary site of Amyloid deposition
or secondarily.
Primary localized corneal amyloidosis consists of two localized inherited corneal involvements,
gelatinous droplike dystrophy and lattice corneal dystrophy types I and III. In these dystro‐
phies the amyloidosis is localized to the cornea without systemic manifestations.
Primary systemic amyloidosis is known as lattice corneal dystrophy type II (LCD II), (also
known as familial amyloidotic polyneuropathy type IV, or Meretoja syndrome.)
Ocular Presentations of Amyloidosis
http://dx.doi.org/10.5772/53910
95
Secondary localized corneal amyloidosis has been observed in a variety of corneal and ocular
diseases such as trichiasis, trachoma, leprosies, sarcoidosis, interstitial keratitis, phlyctenular
keratitis, uveitis, chronic post-traumatic inflammation, glaucoma, and keratoconus.
Secondary systemic amyloidosis does not affect the cornea.[56-59]
11. Gelatinous drop-like corneal dystrophy
Gelatinous drop-like corneal dystrophy (GDCD),( also known as : Lattice corneal dystro‐
phy type III,  Familial  subepithelial  corneal  amyloidosis,  primary familial  amyloidosis  of
the cornea) is a rare corneal dystrophy,first described by Nakaizumi in 1914 and mainly
affects Asian descent but can occurs in diverse ethnic groups throughout the US, Europe
and the Asia.14,15
Inheritance pattern of this dystrophy is Autosomal Dominant and its gene ( TACSTD2
gene ) located on 1p32. Although More than 25 mutations in TACSTD2 gene encoding Tu‐
mor-associated calcium signal transducer 2 have been described,some patients with this corneal
dystrophy doesn’t have this mutation suggesting genetic heterogenicity and probability in‐
volvement of other genes in this autosomal recessive disease.
This dystrophy presents in young adulthood (within the 1st and 2nd decades ) and tends to
be slowly progressive.
Figure 8. Primary, gelatinous droplike dystrophy of the cornea. From Ohnishi Y, Shinoda Y, Ishibashi T, Taniguchi Y:
The origin of amyloid in gelatinous drop-like corneal dystrophy. Curr Eye Res 1982–1983; 2:225–231.
Cornea of this patients on slit-lamp biomicroscopy shows gelatinous white deposits of amy‐
loid in the subepithelial and Bowman Layer, gives multilobulated mulberry-like appearance
to the cornea. These deposits spread laterally and deeply within the stroma with time and
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can make larger nodular lesions leading to photophobia, vision loss and foreign body sensa‐
tion. These lesions marked on with fluorescein staining and sometimes superficial vasculari‐
zation appears on the cornea. Sever vision loss is secondary to coalescence of this deposits
on the cornea surface. Some cases of cataract have been reported in young patients with this
dystrophy. Fusiform appearance of deposits in corneal stroma of some patients resembles
Lattice Corneal Dystrophy (LCD) and some ophthalmologists categorize Gelatinous Drop-
like dystrophy as LCD type III. In this disease, the amyloid contains lactoferrin, but the dis‐
ease is not linked to the lactoferrin gene.
Treatment is with repeated superficial keratectomy because of early recurrences on corneal
grafts. In GDCD, the response to both lamellar and penetrating keratoplasty as well as to a
superficial keratectomy is unsatisfactory as amyloid deposition recurs in the graft within
about 5 years. Soft contact lenses are effective in managing the abnormal epithelial permea‐
bility to decrease recurrences.[56-69]
12. Lattice Corneal Dystrophy (LCD)
Lattice corneal dystrophy is the second form of inherited localized amyloidosis and is the
most common form of corneal stromal dystrophies. This dystrophy typically is a bilateral
disease with an autosomal dominant inheritance which presents at the first and second dec‐
ade of life with symptoms like recurrent corneal erosion and decreased vision.
The term of Lattice for this dystrophy has been originated for the network of thin and deli‐
cate interdigitating branching opacities of the cornea in two separate common types of this
stromal dystrophy. Lattice Corneal Dystrophy type 1 (LCD I ) and its variants are due to a
specific mutation in the TGFBI gene and patients with this form of corneal dystrophy have
no systemic manifestations, but in LCD type II systemic manifestations are inevitable part of
corneal disease and this form resulting from a mutation in Gelsolin (GSN) gene.
Five subtypes of  LCD have been identified,we will  discuss  in  this  section about  Lattice
corneal dystrophy type I, II,III. Other sub-types of this dystrophy are very rare disorders.
[56,70,75]
12.1. Lattice dystrophy type ( I )
This type of LCD is the most common form and also known as Biber-Haab-Dimmer corneal
dystrophy. LCD1 usually presents its manifestations at the end of the first decade of life, but
occasionally it begins in middle life and rarely in infancy and typically is a bilateral disease
although occasional unilateral involvement may occur. Corneal sensation is often decreased
and the network of interdigitating corneal filamentous opacities has some similarity to
nerves, although these lesions are not apparent in all affected members of families with
LCD1. Although LCD 1 is seen most often in the western world but some cases have been
reported from Bulgaria, Spain and China.
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Characteristics Lattice Corneal Dystrophy Gelatinous drop-
like corneal
dystrophy
Type I Type II Type III
Usual age at onset <10 years >20 years >40 years <20 years
Visual acuity Markedly impaired by age 40–
60 years
Usually good until after age
65 years
Impaired after
60 years
Markedly impaired
by age 10–30 years
Systemic
amyloidosis
No Yes No No
Mode of
inheritance
Autosomal dominant Autosomal dominant Autosomal
recessive
Autosomal
recessive
Facies Normal Masklike facial expression,
blepharochalasis, floppy
ears, protruding lips
Normal Normal
Nervous system Normal Cranial and peripheral nerve
palsies
Normal Normal
Skin Normal Dry, itchy, and lax with
amyloid deposits
Normal Normal
Cornea Delicate interdigitating network
of filaments; no lines present at
early stage; lines difficult to see
at late stage
Thick and radially oriented
lines
Thick lines Multiple prominent
subepithelial
nodules
Episodic corneal
erosion
Yes Yes No No
From Hida K, Tsubota Kigasawa K, et al: Clinical features of a newly recognized type of lattice dystrophy. Am J Oph‐
thalmol 1987; 104:241–248, 1987.
Table 2. Comparison of Inherited Varieties of Corneal Amyloidosis.
At the time of presentation in the first or second decade of life Rod-like fine glassy opacities
in the anterior stroma appear and over time this opacities become denser and combine to‐
gether and make a network of linear branching and interdigitating opacities. These opacities
usually are denser anteriorly and centrally but peripheral cornea is usually spared and clas‐
sical branching lattice figures may not be present in all cases. The lines are relatively fine, as
opposed to the more ropy opacities seen in lattice dystrophy Type III.
LCD I in light microscopy reveals Amyloid deposits in anterior stroma and subepithelial region
that may lead to poor adhesion between corneal epithelium and stroma and secondary recur‐
rent corneal erosion. Other pathologic features of this dystrophy in light microscopy include
epithelial atrophy and disruption, degeneration of basal epithelial cells, and focal thinning or
absence of Bowman layer increasing progressively with age and presence of an eosinophilic
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layer between the epithelial basement membrane and Bowman layer. Stromal deposition of the
amyloid substance can lead to distortion of the corneal lamellar architecture. Amyloid deposi‐
tion in this dystrophy shows typical Amyloid histopathologic features including metachroma‐
sia with crystal violet; ultraviolet fluorescence (yellow-green) with Thioflavin T; and orange-
red staining with Congo red and stain with periodic acid-Schiff, and Masson's trichrome,
exhibits dichroism and birefringence previously mentioned in this chapter.
Figure 9. Lattice corneal dystrophy type I. Klintworth Orphanet Journal of Rare Diseases 2009 4:7 doi:
10.1186/1750-1172-4-7
Figure 10. Lattice dystrophy Type 1.HistopathologyusingCongoredstain showstheamyloidaccumulationsthroughout‐
thestromaarrows Yanoff & Duker: Textbook of Ophthalmology, 3rd ed. )
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Figure 11. Lattice corneal dystrophy type I variant. Deposits of amyloid throughout the corneal stroma due to a p.
Ala546Asp mutation in the TFGFBI gene in a patient with a variant of LCD type 1. Eifrig DE Jr, Afshari NA, Buchanan
HW IV, Bowling BL, Klintworth GK: Polymorphic corneal amyloidosis: a disorder due to a novel mutation in the TGFBI
(BIGH3) gene. Ophthalmology 2004, 111:1108-1114
Diagnosis of LCD I is based on clinical findings. As mentioned before; this dystrophy has an
autosomal dominant inheritance and is due to mutation in the TGFBI gene resulting in iso‐
lated amyloid deposition in the cornea without any systemic manifestation.
Recurrent corneal erosions as a common complication of this dystrophy can be manage with
options like therapeutic contact lenses, superficial keratectomy or phototherapeutic keratec‐
tomy. Despite the fact that this dystrophy may recur in the corneal grafts, severe cases of
lattice dystrophy with decreased vision can be treated with lamellar keratoplasty (DALK) or
Penetrating Keratoplasty (PK).[56,70-79]
12.2. lattice dystrophy type II
(Familial amyloid polyneuropathy Type IV (Finnish type), also known as Meretoja's syn‐
drome)
This dystrophy as a part of systemic disease involves corneal stroma bilaterally and is simi‐
lar to LCD I, histopathologically and clinically but fine glass-like lines are randomly scat‐
tered, radially oriented, less numerous, and more delicate, than those in LCD I. Stromal
lattice lines in this dystrophy reach to the peripheral cornea and limbus and central cornea is
almost spared in contrast to LCD I. Although corneal sensitivity and nerve density is re‐
duced in this type of LCD, Lattice lines are not related to corneal nerves. Patients with this
disease are at increased risk of Open-Angle Glaucoma.
This dystrophy is secondary to the GSN (Gelsolin) gene mutation located on chromosome 9.
Gelsolin is an actin severing protein and the abnormal Gelsolin molecule leads to deposition
of highly amyloidogenic protein throughout the body. Amyloid deposits in this systemic
disease can be seen in the conjunctiva, sclera, and ciliary body, along the choriocapillaris, in
the ciliary nerves and vessels, and in the optic nerve. Extraocularly, amyloid is detected in
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arterial walls, peripheral nerves, and glomeruli. The amyloid in this condition is related to
Gelsolin and does not stain for type AA or AP.
LCD II present usually after second decade of life but patients that are homozygous for mu‐
tated GSN gene may reveal symptoms earlier. Recurrent corneal erosions are not a common
complication in LCD II and vision loss does not significantly occur before sixth decade of
life. The pathology is similar to lattice dystrophy Type I. Light microscopy shows amyloid in
the lattice lines as a discontinuous band under Bowman layer and within the sclera.
Figure 12. Mask like facies of patient with familial amyloid polyneuropathy type IV (Meretoja, Finnish type). From Pur‐
cell JJ Jr,Rodrigues M, Chishti MI,et al: Lattice cornealndystrophy associated with familial systemic amyloidosis.Oph‐
thalmology 1983;90:1512–1517.)
Treatment modalities are similar to LCD type I, but exposure keratopathy secondary to fa‐
cial neuropathy in some patients may need additional considerations. [56,80-87]
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Figure 13. Corneal deposits of Meretoja’s syndrome (lattice type II, familial amyloidotic polyneuropathy type IV). Note
the location along the course of corneal nerves. From Purcell JJ, Jr, Rodrigues M, Chishti MI, et al: Lattice corneal dys‐
trophy associated with familial systemic amyloidosis. Ophthalmology 1983;90:1512–1517.
12.3. Lattice dystrophy type III & IV
Lattice dystrophy Type III is an autosomal recessive disease that presents often after forth
decade of life (later that LCD type I). Lattice lines in this dystrophy are thicker than type I
and corneal erosions rarely occur. Amyloid usually deposits in the superficial stroma and
beneath the Bowman’s layer and also can be found in mid-stroma.
LCD IIIA has been described with autosomal dominant inheritance and corneal changes
similar to LCD type III; but in this subtype recurrent corneal erosions are more prevalent.
This disorder is due to a defect in the keratoepithelin gene, demonstrated at various codons.
LCD IV is a late-onset corneal dystrophy that has been reported in Japanese population and
is secondary to mutation in TGFBI gene. In this subtype of LCD amyloid deposition is in
deeper stromal layers of cornea.[88-91]
Figure 14. Thick ropy lattice lines in patient with LCD III. From Hida T, Tsubota K, Kigasawa T, et al: Clinical features of
a newly recognized type of lattice corneal dystrophy. Am J Ophthalmol 1987; 104:241-248.
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13. Polymorphic amyloid degeneration
This is a specific type of corneal amyloid degeneration that generally occurs after fifth dec‐
ade of life. This condition is usually bilateral and incidental finding in elderly without much
affect on vision. In slit-lamp biomicroscopy deposits with punctate glass-like appearance
can be seen in central corneal stroma with extension to descemet’s membrane. Sometimes
these deposits resemble lattice dystrophy although usually these deposits are less denser
than LCD. Histopathologically there is a similarity between polymorphic degeneration and
LCD. The reason of this degeneration has not been clearly described and no treatment is
usually required for this patients.
Climatic proteoglycan stromal keratopathy is another condition similar to spheroidal degen‐
eration of cornea first time described in Saudi Arabia. Patients with this condition have bi‐
lateral oval, central horizontal haziness in anterior stroma that may accompany with
refractile stromal lines but does not usually affect vision. In histopathologic review of these
patients proteoglycan and amyloid deposits have been found.[92,93]
Figure 15. Polymorphic amyloid degeneration of the cornea. From Ohnishi Y, Shinoda Y, Ishibashi T, Taniguchi Y: The
origin of amyloid in gelatinous drop-like dystrophy. Curr Eye Res 1982–1983; 2:225–231.
14. Secondary localized amyloidosis
Wide variety of chronic ocular disorders can lead to corneal amyloid deposition including;
keratoconus, trachoma, phlyctenulosis, leprosy, bullous keratopathy (of any etiology), pro‐
longed contact lens wear, trichiasis, uveitis, and severe retinopathy of prematurity with
glaucoma.
Amyloid Deposits secondary to these conditions are usually subepithelial and appear as
cream-colored nodules very similar to Gelatinous-drop like corneal dystrophy. Corneal vas‐
cularization in relation to primary disorder can be seen. Genetic work up must be done to
rule out systemic inherited amyloidosis.
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Keratoconjunctivitis sicca may be associated with amyloidosis with several mechanisms.
The first mechanism is lacrimal gland infiltration in primary localized amyloidosis, with sec‐
ondary hyposecretion of tears. The second mechanism is orbital nerve infiltration with asso‐
ciated autonomic neuropathy. Reactive (secondary) systemic amyloidosis has been reported
with Sjögren syndrome, a condition frequently heralded by dry eyes. Finally, a systemic im‐
munocyte dyscrasia, with or without systemic amyloidosis may result in neoplastic infiltra‐
tion of the lacrimal gland and associated dry eye.[94-96]
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